Cipher: 2614
Nomenclature: Pathophysiology process of blood clotting in tumor diseases
Study programme: Molecular biosciences
Module: Biomedicine
Case holder:

Slavica Kvolik Prof.dr.sc
Institution of the case holder:

Clinical Hospital Osijek, School of Medicine, J.J. Strossmayer University of Osijek
Contributors - Contractors:

Doc.dr.sc. Tatjana Goranović
Subject status: Electoral College
The year in which the case is submitted: Year I
The semester in which the case is submitted: Semester II
Subject objective:

Understand coagulation disorder in tumors.
Case contents:

Pathophysiology of clotting disorders in tumors, procoagulation phallic fators in tumor diseases, clotting inhibitors in tumor diseases, fibrinolytic system
Non-ovascularization of tumors, density of circulatory in tumors, mechanisms of angiogenesis, enzyme MMP, growth factors VEGF/VPF
Activation of endothelials in malignant diseases, platelet disorders in malignant diseases, clotting disorders related to certain malignant diseases
Experimental models of coagulation research in tumors
Laboratory diagnostics and indicators of clotting disorders in tumors, indications
Clotting disorders after radiation
Effect of chemotherapy of tumor diseases on clotting processes, neoadjuvant chemotherapy, hormonal therapy, local application of cytostatics and clotting, platelet changes after chemotrapy
Effect of heparin on clotting, anti IIa/antiXa effect; antagonists viamina K,
The most common clinical manifestations of clotting disorders codecourse: pulmonary embolism, deep vein thrombosis, disseminated intravascular coagulation
Preventive procedures in preventing the onset of thromboembolic disorders in patients with malignant diseases
Treatment of clotting disorders in tumors, postoperative clotting disorders
Learning outcomes: competences, knowledge, skills that the subject develops:

1. Explain the pathophysiology of clotting in tumors and the recognition of the effect of chemotherapy on clotting.
2. Analyze molecular aspects in the field of pathophysiology of clotting in tumors.
3. Establish the principle of coagulation status analysis on the basis of laboratory findings.
4. Assess the effect of anticoagulation drugs in cancer patients.
5. Propose research in the field of pathophysiology of clotting in tumors based on relevant literature.
ECTS Credits 4
Lectures 10
Seminars (IS) 5
Exercises (E) 5
Altogether 20
The way of teaching and acquiring knowledge:

compulsory attendance of 80% of classes
Searching literature in the field of growth factors and clotting disorders in tumors
Analysis of one scientific paper in the field of pathophysiology of clotting in tumors
Analysis of coagulation status based on laboratory findings
Ways of teaching and acquiring knowledge: (notes)
Monitoring and evaluating students (mark in fat printing only relevant categories) Attendance, Teaching activities, Mandatory seminar work
Rating method: Written exam, Analysis of published publication
Mandatory literature:

1. Šakić K. et al. Script for the subject "Blood clotting disorders in tumor diseases"
2. Šakić K et al. Autotransfusion, thromboprfilax and perioperative bleeding. Faculty of Medicine Zagreb, Medical Publishing, Zagreb.2012.,
3. Šakić Zdravčević K, Šakić L, Bagatin D. Bagatin T. Blood management strategies in vertebral surgery. Orthopaedic anaesthesia and intensive care, Balkan States Anesthesia Days-III Skopje , Macedonia, 18-21. May, 2016, ISBN 978-608-4596-86-8 COBISS. MK-ID 101125898 Skopje 2016; p 27-30
4. Bagatin D, Šakić K, Sturm D,Šakić L, Bagatin T Perioperative coagulation disorders in cancer patients, impact of Thromboprophylaxis. Proceedings /6.Slovenian Congress of Anaesthesiology-International. Ljubljana, Slovenia, May 10th.-12th,2013, Ed.,Novak Jankovich Vesna, ISBN 978-961-6404-26-6, CIP 616-089.5 (082), p 65-69
5. Kvolik, Slavica; Lenz, Bahria; Šakić, Kata; Glavas-Obrovac, Ljubica.
6. Immune-mediated coagulation disorders in cancer patients // Biochemistry and Immunology Intersections / Markotic, Anita at a. (your.). Kerala : Research Signpost, 2008. P. 99-121
7. Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An overview of coagulation disorders in cancer patients. Surg Oncol
Supplementary (recommended) literature:

1. Bagatin D, Šakić K. Bagatin T, Sturm D, Milošević M. Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor? Periodicum Biologorum 2015; 117(2): 291–296
2. Sturm, D; Vazdar, Lj; Bagatin, D; Šakić, K; Hrgović, Z.Perioperative PAI-1 values in surgically treated colorectal carcinoma patients under low molecular weight heparin thromboprophylaxisPerioperative PAI-1 values in surgically treated colorectal carcinoma patients under low molecular weight heparin thromboprophylaxis.. Minerva chirurgica (Testo stampato). 67 (2012) , 4; 343-54
3. Štefančić Lj.Marić S; Maldini B, Banović M, Brozović G, Šakić, Kata.Dynamics of change in coagulation parameters in carcinoma patients with epidural analgesia following liver resection. Periodicum biologorum. 113 (2011) , 2; 187-190
4. Sturm, Deana; Vazdar, L; Bagatin, Dinko; Šakić, Katarina; Hrgovic, Zlatko.
5. Recombinant factor VIIa in the treatment of hemostatic disorders in patients with solid tumors: Recombinant factor VIIa and solid tumors. Tumordiagnostic & Therapie. 2011; 32:345-348
6. Brozović G, Oršolić N,Knezević F, Horvat Knezević A, Benković V, Šakić K, Borojević N, Đikić D.The in vivo genotoxicity of cisplatin, isoflurane and halothane evaluated by alkaline comet assay in Swiss albino mice. Journal of Applied Genetics. 52 (2011) , 3; 355-361
7. Goluza E, Šakic K, Orsolic N.The influence of intravascular volume maintenance with a hydroxyethyl starch solution on coagulation in patients undergoing transurethral resection of the prostate; Period Biol.2011;113:75-79.
8. Kvolik S.Glavas-Obrovac, L., Sakic, K., Margaretic, D., Karner, I. Anaesthetic implications of anticancer chemotherapy . European Journal of Anaesthesiology 2003; 20: 859-871
9. Kvolik S. Brozović G. Clotting disorders in chemotherapy patients. Acta anaesthesiologica Croatica, 2004; 1(7):33-36.
10. Verheul HM, Hoekman K, Lupu F, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000; 6: 166-171.
11. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380.
12. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003; 163: 1801-1815.
13. Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost 2003; 29: 291-300.
14. Di Micco P, Romano M, Niglio A, et al. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis 2001; 33: 546-550.
15. Ozturk M, Sengul N, Dagli M, Kosar A, Bavbek N. Global fibrinolytic capacity in colorectal cancer: a new clue to occult fibrinolysis. Clin Appl Thromb Hemost 2003; 9: 151-154.
16. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
17. Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thromb Res. 2002; 108: 3-13.
18. Szende B, Paku S, Racz G, Kopper L. Effect of Fraxiparine and heparin on experimental tumor metastasis in mice. Anticancer Res 2005; 25: 2869-2872.
19. 11. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP), a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol 2002; 36: 119-123.
How to monitor the quality and performance performance (evaluation):

Questionnaires for examining the attitudes of program participants towards the program and lecturers
(examination of prior knowledge before the start of classes and at the end of the course).
Discussions with students and colleagues.
Tracking each student's progress.
Evaluation of performance by the head of studies and the joint expert committee of the institutions of the holders of the study.